Lymphocyte Predominant Hodgkin's Lymphoma (LPHL)
This information was originally presented on September 21, 2013, at the NCCN 8th Annual Congress: Hematologic Malignancies™ held in New York, New York.
This activity is designed to meet the educational needs of hematologists, oncologists, nurses, pharmacists, and other health care professionals who manage patients with hematologic malignancies.
Following this activity, participants should be able to:
- Summarize the current treatment options and the role of monoclonal antibodies in the management of patients with LPHL
Ranjana H. Advani, MD
Stanford Cancer Institute
- 0.50 Participation
- 0.40 Nurse
- 0.50 Pharmacist
- 0.50 Physician